Amanda M Schalk
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2018First federal award
$3.9MFederal grants as PI9 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
9 awards · $3.9M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 16, 2026 | NIH | SBIR Phase I Validating the reduced immunogenicity of novel human-like asparaginases to de-risk clinical development | $400K | Enzyme by Design Inc. |
| Jul 5, 2024 | NIH | SBIR Phase I Engineering in vivo half-life extension of a novel mammalian asparaginase to increase feasibility of pan-cancer therapy | $400K | Enzyme by Design Inc. |
| Aug 4, 2022 | NIH | SBIR Phase II A novel glutaminase-free mammalian asparaginase with minimized immunogenicity to enable expanded use in cancer therapy | $837K | Enzyme by Design Inc. |
| Aug 24, 2021 | NIH | SBIR Phase II A novel glutaminase-free mammalian asparaginase with minimized immunogenicity to enable expanded use in cancer therapy | $1 | Enzyme by Design Inc. |
| Sep 11, 2020 | NIH | SBIR Phase II A novel glutaminase-free mammalian asparaginase with minimized immunogenicity to enable expanded use in cancer therapy | $1.2M | Enzyme by Design Inc. |
| Aug 31, 2020 | NIH | SBIR Phase I Extending the in vivo half-life of a novel engineered mammalian asparaginase via its binding to human serum albumin | $400K | Enzyme by Design Inc. |
| Jul 14, 2020 | NIH | SBIR Phase I Maximizing the safety profile of a novel cancer therapeutic via the de-immunization of an engineered mammalian asparaginase | $150K | Enzyme by Design Inc. |
| Jul 5, 2019 | NIH | SBIR Phase I Maximizing the safety profile of a novel cancer therapeutic via the de-immunization of an engineered mammalian asparaginase | $300K | Enzyme by Design Inc. |
| Sep 20, 2018 | NIH | STTR Phase I Development of a novel safe and efficacious biologic drug for the treatment of AML | $300K | Enzyme by Design Inc. |
Peer ranks
Federal funding#404
Awards as PI#151
Patents#273
Companies
- Enzyme by Design Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.